【レポートの概要（一部）】
Executive Summary
Section 1: Analyzing the Global Pharmaceutical Industry
A. Historical Perspective of the Global Pharmaceutical Industry
B. Analysis of the Global Pharmaceutical Industry
B.1 Industry Definitions
B.1.1 Pharmaceutical Industry
B.1.2 Bulk Drugs
B.1.3 Formulations
B.2 Industry Statistics
B.3 Industry Value Analysis
B.4 Market Segments
B.5 Market Share Analysis
B.6 Competition in the Industry
B.7 Market Forecast
C. Global Pharmaceutical Industry: Porter’s Five Forces Strategy Analysis
C.1 Introduction
C.2 Bargaining Power of Buyers
C.3 Bargaining Power of Suppliers
C.4 Competitive Rivalry in the Industry
C.5 Threat of New Entrants
C.6 Threat of Substitutes
D. Analysis of the Global OTC Pharmaceutical Industry
D.1 Industry Definition
D.2 Industry Statistics
D.3 Industry Value Analysis
D.4 Market Segments
D.5 Distribution Channels
D.6 Market Share Analysis
D.7 Market Forecast
E. Global OTC Pharmaceutical Industry: Porter’s Five Forces Strategy Analysis
E.1 Introduction
E.2 Bargaining Power of Buyers
E.3 Bargaining Power of Suppliers
E.4 Competitive Rivalry in the Industry
E.5 Threat of New Entrants
E.6 Threat of Substitutes
F. Analysis the Global Generics Industry
F.1 Industry Definition
F.2 Industry Statistics
F.3 Industry Value & Volume Analysis
F.4 Market Segments
F.5 Industry Structure
F.6 Patent Expiries
F.7 Patent Expiries by Therapeutic Areas
F.8 Research & Development in the Industry
F.8.1 Super Generics
F.8.2 Biosimilars
F.9 Market Forecast
G. Global Generics Industry: Porter’s Five Forces Strategy Analysis
G.1 Introduction
G.2 Bargaining Power of Buyers
G.3 Bargaining Power of Suppliers
G.4 Competitive Rivalry in the Industry
G.5 Threat of New Entrants
G.6 Threat of Substitutes
H. Structure of the Global Pharmaceutical Industry
H.1 R&D Pipelines
H.2 Defense against Generic Competition
H.3 Looking at Restructuring and Outsourcing
H.4 Strategic Alliances
I. Analyzing the Industry
I.1 Barriers to Entry
I.2 Lifecycle of a Drug
I.2.1 The Patent System
I.2.2 Drug Lifecycle
I.3 Industry Cost Structure
I.3.1 Types of Costs
I.3.2 Evidence on Cost Structure
I.3.3 Increasing Costs & Risks of Developing New Drugs
I.3.4 Conclusion
I.4 Trends in the Global Pharmaceutical Industry
I.5 Business Environment
I.6 Industry Innovation
I.7 Globalization of the Pharmaceutical Industry
I.8 Role of Genomics
J. Factors Driving Growth & Change in the Global Pharmaceutical Industry
J.1 Introduction
J.2 Growth in the Pharma Market
J.3 Reasons for Growth
J.4 New Product Lines
J.5 Opportunities in CNS Disorders & Oncology Research
J.6 Commercialization of Dormant Compounds
J.7 Generic/Biosimilar Versions of Biologics
K. Challenges Facing the Global Pharmaceutical Industry
K.1 Parallel Trade
K.2 Rising Cost of Healthcare
K.3 Immense Pressure on Industry Revenues
K.4 Uncertainty in Pipeline
K.5 Increasing Risks
K.6 Issues with Outcome-based Pricing
N. Offshoring in the Pharmaceutical Sector
N.1 Introduction
N.1.1 What is Offshoring?
N.1.2 Analyzing the Pharma Value Chain
N.1.3 Employment Scenario of the Pharmaceutical Industry
N.1.4 Why Offshore?
N.1.5 Primary Offshoring Locations
N.2 Offshoring of R&D
N.2.1 India
N.2.2 China
N.2.3 Growth Factors
N.2.4 Challenges & Barriers to Offshoring R&D
N.3 Offshoring of Pharmaceutical Manufacturing Processes
N.3.1 Overview
N.3.2 Biologics Manufacturing
N.3.3 API Manufacturing
N.3.4 Final Dosage Manufacturing
N.3.5 Growth Factors
N.3.6 Challenges & Barriers to Offshoring Manufacturing Processes
Section 2: Analyzing the Global Pharmaceutical Markets
A. Pharmaceutical Industry in Australia
A.1 Industry Statistics
A.2 Industry Value Analysis
A.3 Geographic Segmentation
A.4 Industry Trends
A.5 Production Trends
A.6 Market Share Analysis
A.7 Competition in the Industry
A.8 Industry Outlook
B. Pharmaceutical Industry in Belgium
B.1 Industry Statistics
B.2 Industry Value Analysis
B.3 Geographic Segmentation
B.4 Market Share Analysis
B.5 Competition in the Industry
B.6 Industry Outlook
C. Pharmaceutical Industry in Brazil
C.1 Industry Statistics
C.2 Industry Value Analysis
C.3 Geographic Segmentation
C.4 Market Share Analysis
C.5 Competition in the Industry
C.6 Industry Outlook
D. Pharmaceutical Industry in Canada
D.1 Industry Statistics
D.2 Industry Value Analysis
D.3 Geographic Segmentation
D.4 Market Share Analysis
D.5 Competition in the Industry
D.6 Industry Outlook
E. Pharmaceutical Industry in China
E.1 Industry Statistics
E.2 Industry Value Analysis
E.3 Geographic Segmentation
E.4 Industry Trends
E.5 Production Trends
E.6 Regulatory Framework
E.7 Market for Traditional Chinese Medicine
E.8 Market Share Analysis
E.9 Competition in the Industry
E.10 Industry Outlook
F. Pharmaceutical Industry in Czech Republic
F.1 Industry Statistics
F.2 Industry Value Analysis
F.3 Geographic Segmentation
F.4 Market Share Analysis
F.5 Competition in the Industry
F.6 Industry Outlook
G. Pharmaceutical Industry in Denmark
G.1 Industry Statistics
G.2 Industry Value Analysis
G.3 Geographic Segmentation
G.4 Market Share Analysis
G.5 Competition in the Industry
G.6 Industry Outlook
H. Pharmaceutical Industry in France
H.1 Industry Statistics
H.2 Industry Value Analysis
H.3 Geographic Segmentation
H.4 Market Share Analysis
H.5 Competition in the Industry
H.6 Industry Outlook
I. Pharmaceutical Industry in Germany
I.1 Industry Statistics
I.2 Industry Value Analysis
I.3 Geographic Segmentation
I.4 Market Share Analysis
I.5 Competition in the Industry
I.6 Industry Outlook
J. Pharmaceutical Industry in Hungary
J.1 Industry Statistics
J.2 Industry Value Analysis
J.3 Geographic Segmentation
J.4 Market Share Analysis
J.5 Competition in the Industry
J.6 Industry Outlook
K. Pharmaceutical Industry in India
K.1 Industry Statistics
K.2 Industry Value Analysis
K.3 Geographic Segmentation
K.4 Industry Trends
K.5 Production Trends
K.6 Market Share Analysis
K.7 Competition in the Industry
K.8 Industry Outlook
L. Pharmaceutical Industry in Italy
L.1 Industry Statistics
L.2 Industry Value Analysis
L.3 Geographic Segmentation
L.4 Market Share Analysis
L.5 Competition in the Industry
L.6 Industry Outlook
M. Pharmaceutical Industry in Japan
M.1 Industry Statistics
M.2 Industry Value Analysis
M.3 Geographic Segmentation
M.4 Industry Trends
M.5 Production Trends
M.6 Market Share Analysis
M.7 Competition in the Industry
M.8 Industry Outlook
N. Pharmaceutical Industry in Mexico
N.1 Industry Statistics
N.2 Industry Value Analysis
N.3 Geographic Segmentation
N.4 Market Share Analysis
N.5 Competition in the Industry
N.6 Industry Outlook
O. Pharmaceutical Industry in Netherlands
O.1 Industry Statistics
O.2 Industry Value Analysis
O.3 Geographic Segmentation
O.4 Market Share Analysis
O.5 Competition in the Industry
O.6 Industry Outlook
P. Pharmaceutical Industry in New Zealand
P.1 Industry Statistics
P.2 Industry Value Analysis
P.3 Geographic Segmentation
P.4 Market Share Analysis
P.5 Competition in the Industry
P.6 Industry Outlook
Q. Pharmaceutical Industry in Norway
Q.1 Industry Statistics
Q.2 Industry Value Analysis
Q.3 Geographic Segmentation
Q.4 Market Share Analysis
Q.5 Competition in the Industry
Q.6 Industry Outlook
R. Pharmaceutical Industry in Poland
R.1 Industry Statistics
R.2 Industry Value Analysis
R.3 Geographic Segmentation
R.4 Market Share Analysis
R.5 Competition in the Industry
R.6 Industry Outlook
S. Pharmaceutical Industry in Russia
S.1 Industry Statistics
S.2 Industry Value Analysis
S.3 Geographic Segmentation
S.4 Market Share Analysis
S.5 Competition in the Industry
S.6 Industry Outlook
T. Pharmaceutical Industry in Singapore
T.1 Industry Statistics
T.2 Industry Value Analysis
T.3 Geographic Segmentation
T.4 Market Share Analysis
T.5 Competition in the Industry
T.6 Industry Outlook
U. Pharmaceutical Industry in South Africa
U.1 Industry Statistics
U.2 Industry Value Analysis
U.3 Geographic Segmentation
U.4 Market Share Analysis
U.5 Competition in the Industry
U.6 Industry Outlook
V. Pharmaceutical Industry in South Korea
V.1 Industry Statistics
V.2 Industry Value Analysis
V.3 Geographic Segmentation
V.4 Market Share Analysis
V.5 Competition in the Industry
V.6 Industry Outlook
W. Pharmaceutical Industry in Spain
W.1 Industry Statistics
W.2 Industry Value Analysis
W.3 Geographic Segmentation
W.4 Market Share Analysis
W.5 Competition in the Industry
W.6 Industry Outlook
X. Pharmaceutical Industry in Sweden
X.1 Industry Statistics
X.2 Industry Value Analysis
X.3 Geographic Segmentation
X.4 Market Share Analysis
X.5 Competition in the Industry
X.6 Industry Outlook
Y. Pharmaceutical Industry in Taiwan
Y.1 Industry Statistics
Y.2 Industry Value Analysis
Y.3 Geographic Segmentation
Y.4 Market Share Analysis
Y.5 Competition in the Industry
Y.6 Industry Outlook
Z. Pharmaceutical Industry in United Kingdom
Z.1 Industry Statistics
Z.2 Industry Value Analysis
Z.3 Geographic Segmentation
Z.4 Market Share Analysis
Z.5 Competition in the Industry
Z.6 Industry Outlook
AA. Pharmaceutical Industry in the United States
AA.1 Industry Statistics
AA.2 Industry Value Analysis
AA.3 Geographic Segmentation
AA.4 Market Share Analysis
AA.5 Competition in the Industry
AA.6 Industry Outlook
Section 3: Analyzing the Major Market Players
A. Abbott Laboratories
A.1 Corporate Profile
A.2 Business Segment Analysis
A.3 Financial Analysis
A.4 Ratio Analysis
A.5 Major Products & Services
A.6 SWOT Analysis
B. Allergan, Inc.
B.1 Corporate Profile
B.2 Business Segment Analysis
B.3 Financial Analysis
B.4 Ratio Analysis
B.5 Major Products & Services
B.6 SWOT Analysis
C. Amgen, Inc.
C.1 Corporate Profile
C.2 Business Segment Analysis
C.3 Financial Analysis
C.4 Ratio Analysis
C.5 Major Products & Services
C.6 SWOT Analysis
D. Apotex, Inc.
D.1 Corporate Profile
D.2 Business Segment Analysis
D.3 Financial Analysis
D.4 Ratio Analysis
D.5 Major Products & Services
D.6 SWOT Analysis
E. Aspen Pharmacare Holdings Limited
E.1 Corporate Profile
E.2 Business Segment Analysis
E.3 Financial Analysis
E.4 Ratio Analysis
E.5 Major Products & Services
E.6 SWOT Analysis
F. Astellas Pharma
F.1 Corporate Profile
F.2 Business Segment Analysis
F.3 Financial Analysis
F.4 Ratio Analysis
F.5 Major Products & Services
F.6 SWOT Analysis
G. AstraZeneca
G.1 Corporate Profile
G.2 Business Segment Analysis
G.3 Financial Analysis
G.4 Ratio Analysis
G.5 Major Products & Services
G.6 SWOT Analysis
H. Baxter International
H.1 Corporate Profile
H.2 Business Segment Analysis
H.3 Financial Analysis
H.4 Ratio Analysis
H.5 Major Products & Services
H.6 SWOT Analysis
I. Bayer AG
I.1 Corporate Profile
I.2 Business Segment Analysis
I.3 Financial Analysis
I.4 Ratio Analysis
I.5 Major Products & Services
I.6 SWOT Analysis
J. Boehringer Ingelheim
J.1 Corporate Profile
J.2 Business Segment Analysis
J.3 Financial Analysis
J.4 Ratio Analysis
J.5 Major Products & Services
J.6 SWOT Analysis
K. Bristol-Myers Squibb
K.1 Corporate Profile
K.2 Business Segment Analysis
K.3 Financial Analysis
K.4 Ratio Analysis
K.5 Major Products & Services
K.6 SWOT Analysis
L. Chugai Pharmaceutical
L.1 Corporate Profile
L.2 Business Segment Analysis
L.3 Financial Analysis
L.4 Ratio Analysis
L.5 Major Products & Services
L.6 SWOT Analysis
M. Daewoong Pharmaceutical Co Ltd.
M.1 Corporate Profile
M.2 Business Segment Analysis
M.3 Financial Analysis
M.4 Ratio Analysis
M.5 Major Products & Services
M.6 SWOT Analysis
N. Daiichi Sankyo Company
N.1 Corporate Profile
N.2 Business Segment Analysis
N.3 Financial Analysis
N.4 Ratio Analysis
N.5 Major Products & Services
N.6 SWOT Analysis
O. Eisai Co., Ltd
O.1 Corporate Profile
O.2 Business Segment Analysis
O.3 Financial Analysis
O.4 Ratio Analysis
O.5 Major Products & Services
O.6 SWOT Analysis
P. Eli Lilly and Company
P.1 Corporate Profile
P.2 Business Segment Analysis
P.3 Financial Analysis
P.4 Ratio Analysis
P.5 Major Products & Services
P.6 SWOT Analysis
Q. F. Hoffmann-La Roche
Q.1 Corporate Profile
Q.2 Business Segment Analysis
Q.3 Financial Analysis
Q.4 Ratio Analysis
Q.5 Major Products & Services
Q.6 SWOT Analysis
R. GlaxoSmithKline Plc
R.1 Corporate Profile
R.2 Business Segment Analysis
R.3 Financial Analysis
R.4 Ratio Analysis
R.5 Major Products & Services
R.6 SWOT Analysis
S. Johnson & Johnson
S.1 Corporate Profile
S.2 Business Segment Analysis
S.3 Financial Analysis
S.4 Ratio Analysis
S.5 Major Products & Services
S.6 SWOT Analysis
T. Lupin Limited
T.1 Corporate Profile
T.2 Business Segment Analysis
T.3 Financial Analysis
T.4 Ratio Analysis
T.5 Major Products & Services
T.6 SWOT Analysis
U. Merck & Co.
U.1 Corporate Profile
U.2 Business Segment Analysis
U.3 Financial Analysis
U.4 Ratio Analysis
U.5 Major Products & Services
U.6 SWOT Analysis
V. Novartis AG
V.1 Corporate Profile
V.2 Business Segment Analysis
V.3 Financial Analysis
V.4 Ratio Analysis
V.5 Major Products & Services
V.6 SWOT Analysis
W. Pfizer
W.1 Corporate Profile
W.2 Business Segment Analysis
W.3 Financial Analysis
W.4 Ratio Analysis
W.5 Major Products & Services
W.6 SWOT Analysis
X. Richter Gedeon Vegyeszeti Gyar Nyrt
X.1 Corporate Profile
X.2 Business Segment Analysis
X.3 Financial Analysis
X.4 Ratio Analysis
X.5 Major Products & Services
X.6 SWOT Analysis
Y. Sanofi SA
Y.1 Corporate Profile
Y.2 Business Segment Analysis
Y.3 Financial Analysis
Y.4 Ratio Analysis
Y.5 Major Products & Services
Y.6 SWOT Analysis
Z. Shanghai Pharmaceuticals Holding Co. Ltd.
Z.1 Corporate Profile
Z.2 Business Segment Analysis
Z.3 Financial Analysis
Z.4 Ratio Analysis
Z.5 Major Products & Services
Z.6 SWOT Analysis
AA. Sumitomo Dainippon Pharma
AA.1 Corporate Profile
AA.2 Business Segment Analysis
AA.3 Financial Analysis
AA.4 Ratio Analysis
AA.5 Major Products & Services
AA.6 SWOT Analysis
BB. Takeda Pharmaceutical Company Limited
BB.1 Corporate Profile
BB.2 Business Segment Analysis
BB.3 Financial Analysis
BB.4 Ratio Analysis
BB.5 Major Products & Services
BB.6 SWOT Analysis
CC. Teva Pharmaceutical Industries
CC.1 Corporate Profile
CC.2 Business Segment Analysis
CC.3 Financial Analysis
CC.4 Ratio Analysis
CC.5 Major Products & Services
CC.6 SWOT Analysis
DD. Aurobindo Pharma Ltd
DD.1 Corporate Profile
DD.2 Business Segment Analysis
DD.3 Financial Analysis
DD.4 Ratio Analysis
DD.5 Major Products & Services
EE. Cadila Healthcare
EE.1 Corporate Profile
EE.2 Business Segment Analysis
EE.3 Financial Analysis
EE.4 Ratio Analysis
EE.5 Major Products & Services
FF. China National Accord Medicines Corporation Ltd
FF.1 Corporate Profile
FF.2 Business Segment Analysis
FF.3 Financial Analysis
FF.4 Ratio Analysis
FF.5 Major Products & Services
GG. Cipla Ltd
GG.1 Corporate Profile
GG.2 Business Segment Analysis
GG.3 Financial Analysis
GG.4 Ratio Analysis
GG.5 Major Products & Services
HH. Dr. Reddy’s Laboratories Limited
HH.1 Corporate Profile
HH.2 Business Segment Analysis
HH.3 Financial Analysis
HH.4 Ratio Analysis
HH.5 Major Products & Services
II. Hanmi Science Co Ltd
II.1 Corporate Profile
II.2 Business Segment Analysis
II.3 Financial Analysis
II.4 Ratio Analysis
II.5 Major Products & Services
JJ. Harbin Pharmaceutical Group Co. Ltd.
JJ.1 Corporate Profile
JJ.2 Business Segment Analysis
JJ.3 Financial Analysis
JJ.4 Ratio Analysis
JJ.5 Major Products & Services
KK. Jubilant Life Sciences Ltd
KK.1 Corporate Profile
KK.2 Business Segment Analysis
KK.3 Financial Analysis
KK.4 Ratio Analysis
KK.5 Major Products & Services
LL. Mylan Laboratories Ltd
LL.1 Corporate Profile
LL.2 Business Segment Analysis
LL.3 Financial Analysis
LL.4 Ratio Analysis
LL.5 Major Products & Services
MM. Pharmstandard OJSC
MM.1 Corporate Profile
MM.2 Business Segment Analysis
MM.3 Financial Analysis
MM.4 Ratio Analysis
MM.5 Major Products & Services
NN. Ranbaxy Laboratories
NN.1 Corporate Profile
NN.2 Business Segment Analysis
NN.3 Financial Analysis
NN.4 Ratio Analysis
NN.5 Major Products & Services
OO. Sun Pharmaceutical Industries
OO.1 Corporate Profile
OO.2 Business Segment Analysis
OO.3 Financial Analysis
OO.4 Ratio Analysis
OO.5 Major Products & Services
PP. Taisho Pharmaceutical Co., Ltd.
PP.1 Corporate Profile
PP.2 Business Segment Analysis
PP.3 Financial Analysis
PP.4 Ratio Analysis
PP.5 Major Products & Services
QQ. Chiesi Farmaceutici SpA
RR. Dong-A Pharmaceutical Co. Ltd
SS. Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.
TT. Yunnan Baiyao Group
Section 4: Glossary of Terms
【レポート販売概要】
■ タイトル：世界の製薬産業分析2015■ 英文：Analyzing the Global Pharmaceutical Industry 2015
■ 発行日：2015年2月
■ 調査会社：Aruvian’s R’search
■ 商品コード：ARUV50201
■ 調査対象地域：グローバル
- アメリカのオフィス向けコーヒー・サービス市場2016-2020About Office Coffee Service Office coffee services involve the installation of coffee vending machines in offices, maintained and supplied by various vendors, to ensure round-the-clock availability of coffee. The coffee machine is considered an important investment by employers. Office coffee services are considered to enhance employee productivity, and many employees like to view high-quality off …
- 分裂感情障害治療のグローバル臨床試験動向（2014年下半期）Schizoaffective Disorder Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" provides data on the Schizoaffective Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizoaffective Disorder. It includes an overview of the trial num …
- ビリルビンの市場別検査数および販売予測（2013-2018/体外診断/世界主要国）This new report from Venture Planning Group provides analysis of Bilirubin testing, including clinical significance, current and emerging diagnostic procedures, as well as test volume and sales forecasts by country and market segment. Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA Market Segmentation Centralized Testing - Hospitals - Commercial/Private Laboratories P …
- 抗高脂血症薬の世界市場：薬物クラス別（スタチン、PCSK9阻害剤、胆汁酸封鎖剤、コレステロール吸収阻害剤、フィブリン酸誘導体、配合）The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,864 million by 2026, registering a CAGR of 7.5% from 2019 to 2026. Lipids are defined as the organic compounds that are fatty acids. These fatty acids are essential and serve as building blocks of the cellular membranes in the living organisms. However, surge in level of lipids in the bloo …
- アドバンストセラミックスの世界市場：チタン酸鉛セラミック、アルミナセラミックス、ジルコニアセラミックス、炭化けい素セラミックスAdvanced ceramics is defined as a highly developed, high-strength ceramic material, which is primarily corrosion-resistant, lightweight, non-metallic and inorganic and possesses specific functional attributes. Advanced ceramics are used for engineering applications which possesses inherent characteristics such as ferroelectric behaviour, semi conductivity, non-linear resistance, and high stiffness …
- 世界のSkincare市場：M&A動向（2014年4月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global skincare market during April 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global skincare market throughout the month. Additionally, the report provides an overview of all the partneri …
- ラボ情報科学の世界市場：CDS、EDC、LES、ECM、ELN、LIMS、SDMSThe global laboratory informatics market is expected to reach USD 2.97 Billion by 2021 from an estimated value of USD 2.20 Billion in 2016 growing at a CAGR of 6.2% during the forecast period. The laboratory informatics market is segmented on the basis of product type, deployment model, component, industry, and region. Based on product type, the market is further segmented into Electronic Data Cap …
- 世界における小型自動車用ルーフシステム市場（2008-2028）This latest just-auto report edition offers a global review of the OE roof systems sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE roof systems market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategies and prosp …
- タブレットPC用タッチパネルの世界市場2016-2020About Tablet Touch Panel A touch panel is a two-dimensional sensing device that comes in the form of a transparent sheet, which is integrated into devices for providing a sensing and feedback system. Touch panels consist of multiple layers that track and convert movements on screen into electrical signals, which are then sent to the processor to perform the required action on the device. These tou …
- Osteonecrosis：グローバル臨床試験レビューH2, 2013Osteonecrosis Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Osteonecrosis Global Clinical Trials Review, H2, 2013" provides data on the Osteonecrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteonecrosis. It includes an overview of the trial numbers and their recruitment status as per the …
- フマル酸の世界市場分析：用途別（食品＆飲料、ロジン紙サイズ、UPR、アルキド樹脂）、セグメント予測、-2020Global fumaric acid market is expected to reach USD 764.8 million by 2020. Increasing convenience food demand coupled with growing middle class per capita disposable income in Asia Pacific and Latin America is expected to drive the global fumaric acid market over the forecast period. Introduction of ethnic and exotic flavors by food & beverages manufacturers is also expected to prompt demand growt …
- フタル酸ジイソノニル可塑剤の世界市場The report covers the global DINP plasticizer market and segments the market on the basis of application and geography. The statistics for the overall market and its sub-markets have been provided with respect to volume (KT) and value (USD Million). The global DINP plasticizer market was valued at $4,285.2 million in 2014 and is projected to grow its market value at a CAGR 7.1% from 2014 to 2019. …
- 動力用鉛蓄電池の世界市場2018-2022About Motive Lead-Acid Battery The Lead-acid battery is the oldest secondary battery technology available in the global battery market, which is extensively used in numerous applications such as automotive, motive, stationary applications. It is majorly used owing to its cranking property, which provides the power with short span. Motive lead-acid battery refers to industrial lead-acid battery, wh …
- ポリウレタン接着剤の世界市場予測（～2021年）The global polyurethane (PU) adhesives market is projected to reach USD 9.38 Billion by 2021, registering a CAGR of 6.8% between 2016 and 2021. Increasing building & construction activities and growth in production of automotive are increasing the demand for PU adhesives. Emerging middle-class population in developing countries such as China, India, and Brazil have triggered the growth of the PU a …
- マグネシウムの世界市場2016-2020About Magnesium Magnesium is the third most abundant metal found in the earth’s crust with a valence of two, and 1s2, 2s2, 2p6, 3s2, 3p6, 3d5, and 4s2 electron configurations. It belongs to 2A group of the periodic table with atomic number 12. It occurs in three isotopes: 24Mg, 25Mg, and 26Mg. Magnesium bonds with other elements very easily and is rarely found in the pure form. Magnesium is found …
